Ligand Pharma (LGND) Tops Q2 EPS by 141c

Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.81, $1.41 better than the analyst estimate of $0.40. Revenue for the quarter came in at $18.42 million versus the consensus estimate of $17 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c